Related Experiment Video
Updated: Jul 15, 2026
09:29
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Scaffold targeting drug-resistant colon cancers
Katerina Otrubova1, Kathleen L McGuire, Shelli R McAlpine
1Department of Chemistry and Biochemistry, 5500 Campanile Road, San Diego State University, San Diego, California 92182-1030, USA.
Journal of Medicinal Chemistry
|April 7, 2007
Summary
Researchers discovered five new sansalvamide A derivatives effective against drug-resistant colon cancer. These compounds show promise as novel colon cancer treatments due to their targeted cytotoxicity and unique structure.
Area of Science:
- Natural Product Chemistry
- Oncology
- Medicinal Chemistry
Background:
- Colon cancer poses a significant health challenge, with drug resistance limiting treatment efficacy.
- Existing therapies for colon cancer often lack specificity and can be ineffective against resistant strains.
Purpose of the Study:
- To identify novel therapeutic agents for multidrug-resistant (MDR) colon cancer.
- To explore the potential of sansalvamide A derivatives as targeted colon cancer treatments.
Main Methods:
- Synthesis and characterization of five sansalvamide A derivatives.
- In vitro evaluation of cytotoxicity against multiple drug-resistant colon cancer cell lines.
- Assessment of selectivity against noncancerous cell lines.
Main Results:
- Five sansalvamide A derivatives exhibited potent cytotoxicity against MDR colon cancer cell lines.
- These analogs demonstrated selectivity, sparing noncancerous cells.
- The identified compounds possess structural features distinct from current colon cancer therapeutics.
Conclusions:
- Sansalvamide A serves as a privileged scaffold for developing new treatments for drug-resistant colon cancer.
- The novel derivatives represent promising candidates for further investigation in colon cancer therapy.
- This study highlights a new avenue for overcoming therapeutic resistance in colon cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...